The three finalists for 2010’s European Biotechnica Award — the prestigious prize aimed at European-based biotechnology companies that have developed innovative products, services and associated business ideas — have been announced. They are Addex Pharmaceuticals (Switzerland), Apeiron Biologics (Austria) and Galapagos Genomics (Belgium).
Addex Pharmaceuticals, based near Geneva, researches and develops agents used in products for treating disorders affecting the central nervous system The Viennese biotech company Apeiron Biologics specializes in the development of enzyme-based biotherapies for treating ARDS (acute respiratory distress syndrome). Galapagos Genomics — the subject of a recent Pharm Exec Europe profile — develops pharmaceutical products for the treatment of bone and joint disease, including bone metastases.
The winner will be announced on 4 October, during the opening ceremony of this year’s Biotechnica event in Hannover, Germany. The winning company will receive prizes worth a total of €75,000.
Further information can be found here.